Lupus is a chronic, autoimmune disease that causes inflammation, particularly of the skin, joints, blood, and kidneys. Patients with lupus produce antibodies against their own proteins. Patients also have immune T cells that produce a protein called IL-2, which normally usually protects against infection, at lower than typical levels. In a study appearing in the April 1 print edition of The Journal of Clinical Investigation, George Tsokos and colleagues from the Walter Reed Army Institute of Research explore the mechanisms underlying this decreased IL-2 production.

The researchers find that sera from lupus patients contains antibodies that bind to T cells and activate a complex cellular signaling cascade that ultimately results in decreased IL-2 production. This deficiency in IL-2 could result in the autoantibody production that occurs in lupus.

In an accompanying commentary, Gary Kammer of Arthritis Associates, Inc points out "the contribution by Tsokos and his colleaguesprovides a new appreciation and insight into how the microenvironment in lupus can further impinge on a defective T cell to inhibit IL-2 production. From such studies will come the inspiration and novel approaches necessary to develop therapeutic tools to abate disease and improve the quality of life of our patients."

'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212 342-4159
Journal of Clinical Investigation
1-Apr-2005

Page: 1
Related biology news :

1. New research identifies anti-viral protein that may predict who might be at risk to develop lupus
2. New biomarkers for lupus found
3. Lupus Research Institute awards $4.5 million to explore new approaches to lupus
4. Resetting epigenetic code could aid lupus patients
5. Lupus Research Institute awards $4.5 million to advance new science in lupus
6. Despite causes of lupus proving complex, critical checkpoint suggesting new therapy is revealed
7. Genes tied to abnormal immune response in mice with lupus
8. UT Southwestern researchers locate gene family involved in determining potential for acquiring lupus
9. Experimental lupus drug may also work against atherosclerosis
10. Newly created cancer stem cells could aid breast cancer research
11. ESF EURYI award winner aims to stop cancer cells reading their own DNA